Sodium-glucose cotransporter 2 (SGLT2) inhibitors have become a significant therapeutic option for the management of heart failure (HF), demonstrating efficacy that extends beyond their initial function in glycemic control for patients with type 2 diabetes mellitus (T2DM). This evidence concerns the gene SLC5A2 and hydrops fetalis.